MGMT and neoplasm: Advances in tumor genomics have identified clinically relevant genetic alterations and epigenetic signatures in GBM, but O (6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation remains one of the few molecular markers predictive of response to standard therapy [3].